Factor | Set 1 | Set 2 | Set 3 | Set 4 | Set 5 | Total | |
---|---|---|---|---|---|---|---|
No of patients | 169 | 488 | 167 | 291 | 407 | 1,522 | |
Events | 20 | 55 | 39 | 39 | 82 | 235 | |
Patient material I a | 30 | 9 | 66 | 39 | 77 | 221 | |
Patient material II a | 0 | 0 | 0 | 67 | 99 | 166 | |
Patient material III a | 28 | 100 | 5 | 27 | 57 | 217 | |
Patient material IV a | 16 | 109 | 9 | 145 | 100 | 379 | |
Patient material V a | 95 | 270 | 87 | 13 | 74 | 539 | |
Age median, years | 45 | 65 | 53 | 61 | 61 | 60 | |
Age range, years | 28-50 | 50-90 | 27-93 | 30-88 | 33-89 | 27-93 | |
Tumor size | |||||||
≤ 20 mm | 113 (67)b | 364 (75) | 68 (41) | 115 (40) | 208 (51) | 868 (57) | |
>20 mm | 56 (33) | 124 (25) | 99 (59) | 176 (60) | 199 (49) | 654 (43) | |
Lymph nodes | |||||||
Negative | 169 | 488 | 0 | 291 | 0 | 948 (62) | |
1-3 positive | 0 | 0 | 167 | 0 | 407 | 574 (38) | |
ER status | |||||||
Positive | 131 (78) | 399 (82) | 122 (73) | 235 (81) | 329 (81) | 1,216 (80) | |
Negative | 38 (22) | 89 (18) | 45 (27) | 56 (19) | 78 (19) | 306 (20) | |
PgR status | |||||||
Positive | 46 (71) | 121 (61) | 56 (70) | 168 (63) | 200 (63) | 591 (64) | |
Negative | 19 (29) | 76 (39) | 24 (30) | 100 (37) | 118 (37) | 337 (36) | |
Missing | 104 | 291 | 87 | 23 | 89 | 594 | |
Histological grade | |||||||
1 | 41 (24) | 136 (28) | 19 (11) | 32 (11) | 67 (17) | 295 (20) | |
2 | 82 (49) | 250 (51) | 97 (58) | 166 (57) | 233 (57) | 828 (54) | |
3 | 46 (27) | 102 (21) | 51 (31) | 93 (32) | 107 (26) | 399 (26) | |
Ki67 | |||||||
Low | 109 (64) | 343 (70) | 111 (66) | 210 (72) | 315 (77) | 1,088 (71) | |
Highc | 60 (36) | 145 (30) | 56 (34) | 81 (28) | 92 (23) | 434 (29) | |
HER2 status | |||||||
Negative | 54 (92) | 142 (87) | 62 (84) | 216 (86) | 249 (88) | 723 (87) | |
Positived | 5 (8) | 21 (13) | 12 (16) | 36 (14) | 33 (12) | 107 (13) | |
Missing | 110 | 325 | 93 | 39 | 125 | 692 | |
Adjuvant endocrine treatment | |||||||
Yes | 0 | 0 | 0 | 291 | 407 | 698 (46) | |
No | 169 | 488 | 167 | 0 | 0 | 824 (54) |